Zydus Cadila to sell one of its animal health business for Rs 2,921 cr
File photo
Zydus Cadila said on Wednesday it has signed agreements to sell one of its animal health business companies to Multiples Alternate Asset Management led consortium for Rs 2,921 crore. The consortium includes Canada Pension Plan Investment Board and RARE Enterprises. The slump sale transaction is expected to be complete within 90 days.
Buyers of CadilaâÂÂs Animal health Business include: Canada Pension Plan Investment Board & Rakesh JhunjhunwalaâÂÂs RARE Enterprises. ItâÂÂs been acquired through an SPV (Zenex Animal Health) pic.twitter.com/1LaZttOZza CNBC-TV18 (@CNBCTV18Live) May 12, 2021
Read more about Benchmarks trade lower; breadth remains positive on Business Standard. The domestic equity indices continued trading with modest losses in afternoon trade. The Nifty hovered above 14,750 mark.
Uniindia: Mumbai, May 12 (UNI) Zydus Animal Health and Investments Limited (ZAHL), a wholly owned material subsidiary of Cadila Healthcare Limited, has entered into a Business Transfer Agreement (BTA) and other Ancillary Agreements (Definitive Agreements) to sell and transfer its Animal Healthcare Established Markets Undertaking to Multiples Alternate Asset Management led consortium.
Equity platform Multiples-led consortium buys Zydus Animal Health biz for Rs 2921 Cr
Equity platform Multiples-led consortium buys Zydus Animal Health biz for Rs 2921 Cr
12 May 2021 | News Multiples, along with its consortium partners, will acquire 100% business of Zydus AH through a slump sale transaction
Image credit- shutterstock.com
Private equity platform Multiples Alternate Asset Management (Multiples) led consortium, through an SPV controlled by them, have signed a Business Transfer Agreement (BTA) and other Ancillary Agreements to acquire Animal Healthcare Established Markets Undertaking (Zydus AH).
The consortium including Multiples, Canada Pension Plan Investment Board (CPP Investments) and RARE Enterprises, is buying the animal health business of Zydus AH focused on India and certain other countries on a going concern basis via a slump sale from Zydus Animal Health and Investments Limited (ZAHL), a wholly owned subsidiary of Cadila Healthcare.